<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02812043</url>
  </required_header>
  <id_info>
    <org_study_id>391/2558(EC1)</org_study_id>
    <nct_id>NCT02812043</nct_id>
  </id_info>
  <brief_title>Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis</brief_title>
  <official_title>Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the efficacy and safety of amorolfine, long-pulsed Nd:YAG laser
      and the combination between amorolfine and long-pulsed Nd:YAG in treating the
      non-dermatophyte and mixed-infection onychomycosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Onychomycosis is the most common cause of nail deformities resulting with more than 50% of
      the patients with abnormal nails. From the institution of dermatology of Thailand, it
      confirmed that 1.7% of Thai population have onychomycosis. Most of the patients aged between
      40-60 years old with female predominated. The common cause of onychomycosis worldwide is
      dermatophyte group, found in more than 50% of the patients. However, in Thailand, the study
      showed that 51.6% of patients with onychomycosis were infected by non-dermatophyte group
      especially Neoscytalidium spp.

      The goal standard treatment for onychomycosis was oral anti-fungal drugs such as Fluconazole,
      Itraconazole and Terbinafine. But many patients were limited to the oral medications due to
      drug interaction between other CYP P2C9 inhibition such as statins, causing the risk of
      rhabdomyolysis and hepatotoxicity. Even though these medications are effective against
      dermatophytes. The non-dermatophytes which were the leading pathogens for onychomycosis in
      Thailand tends to be resistant to the oral medications. Therefore topical and other
      modalities have become an important role for treating those non-dermatophytes onychomycosis
      such as topical anti-fungals, topical urea cream and laser treatment. So far, no standard
      treatment has been made in order to treat the non-dermatophyte onychomycosis causing problems
      to both patients and physicians in Thailand.

      Amorolfine is a morpholine derivative used in topical anti-fungal that inhibits the
      biosynthesis of the fungal cell membrane and showed fungicidal activities. From the previous
      study, amorolfine is an effective topical treatment against non-dermatophyte onychomycosis
      with 52-55% mycological cure rate and the clinical cure rate varied from 12.7%-54% depending
      on the studies. The side effects were minimal and the application was simple to use. So
      amorolfine is used as a first line treatment for non-dermatophyte onychomycosis in our
      practice. However, with the long treatment (from 6 months up to 1 year) and the low
      mycological cure rate newer modality had been studied to deal with this problematic
      pathogens.

      Long-pulsed Nd:YAG laser had been used to treat onychomycosis with a promising result. In
      2013, Kostas Kalokasidis used long-pulsed Nd:YAG for the onychomycosis and showed a 94.5%
      mycological cure rate with no relapse of the disease within 3 months. Later on, Rungsima
      Wanitphakdeedecha M.D. tried the long-pulsed Nd:YAG to treat onychomycosis and found the
      significant result that long-pulsed Nd:YAG can cure up to 95.42% onychomycosis from
      non-dermatophyte group. But the protocol was performed the laser treatment every 2 weeks for
      1 month which made it difficult for the patient to come to the hospital, moreover the
      duration to treat onychomycosis might needed to be longer.

      So the investigators came up with this study to compare the efficacy of long-pulsed Nd:YAG
      with 4-week intervals to the amorolfine and the combination of both Nd:YAG and amorolfine to
      see the mycological result and also the clinical improvement.

      The treatment and KOH examination and fungal culture will be performed every month for 4
      months, and then the follow up will be at 6 months after the first treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mycological cure rate in patients with onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>6 months after treatment</time_frame>
    <description>Mycological cure defined as negative Mycological culture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mycological cure rate in patients with onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>1 month after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure rate in patients with onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>2 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure rate in patients with onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants who develop paronychia after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>1 month after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants who develop paronychia after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>2 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants who develop paronychia after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants who develop paronychia after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain score in participants who received long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>1 month after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain score in participants who received long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>2 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain score in participants who received long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain score in participants who received long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>4 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of nail involvement of onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>1 month after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of nail involvement of onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>2 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of nail involvement of onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>3 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of nail involvement of onychomycosis after Amorolfine, long-pulsed Nd:YAG and the adjunct treatment</measure>
    <time_frame>6 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Non-dermatophyte Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Amorolfine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long-pulsed Nd:YAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of patients will receive only the long-pulsed Nd:YAG (CynergyÂ®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amorolfine+Long-pulsed Nd:YAG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1,064nm Long-pulsed Nd:YAG</intervention_name>
    <description>Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails</description>
    <arm_group_label>Long-pulsed Nd:YAG</arm_group_label>
    <arm_group_label>Amorolfine+Long-pulsed Nd:YAG</arm_group_label>
    <other_name>Dualis SP; Fotona, Lujbljana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amorolfine</intervention_name>
    <description>Amorolfine nail lacquer will be applied by the patient once a week on the infected nails</description>
    <arm_group_label>Amorolfine</arm_group_label>
    <arm_group_label>Amorolfine+Long-pulsed Nd:YAG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients aged more than 18 years old.

          2. The patients were diagnosed with non-dermatophytes or mixed-infection onychomycosis
             from both KOH examination and fungal cultured.

          3. The patients did not have any prior anti-fungal treatment within 6 months

          4. The patients did not receive any vasodilator drugs or isotretinoin within 6 months

          5. The patients who are willing to participate, and accept the methods and risk

        Exclusion Criteria:

          1. The patients who suffered other medical dermatologic condition associated with
             onychomycosis such as psoriasis, paronychia etc.

          2. The patients who took immunosuppressive drugs, or the immunocompromised host.

          3. The patients who had severe vascular disease, such as severe DVT, or poor capillary
             refill time.

          4. The patients who had onychomycosis which involved in nail matrix.

          5. Pregnancy or lactation.

          6. The patients who had problems communication or have difficulty travel to the faculty
             for the checkup.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Dermatology Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charussri Leeyaphan, MD</last_name>
      <phone>6624194333</phone>
      <email>charussrilee@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2015</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>September 3, 2017</last_update_submitted>
  <last_update_submitted_qc>September 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>onychomycosis</keyword>
  <keyword>amorolfine</keyword>
  <keyword>long-pulsed Nd:YAG</keyword>
  <keyword>fungal infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amorolfine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

